Adolor (ADLR) announces positive results from its Phase 2 studies of a non-cancer OIC and GI...

|By:, SA News Editor

Adolor (ADLR) announces positive results from its Phase 2 studies of a non-cancer OIC and GI pain treatment. The firm's CEO says the drugmaker will initiate more studies and share data shortly. Shares +9.1% premarket. (PR)